These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
522 related articles for article (PubMed ID: 32234362)
1. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362 [TBL] [Abstract][Full Text] [Related]
2. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. Schwartzberg LS; Vidal GA Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641 [TBL] [Abstract][Full Text] [Related]
3. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR Sammons S; Shastry M; Dent S; Anders C; Hamilton E Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379 [TBL] [Abstract][Full Text] [Related]
4. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL). Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933 [TBL] [Abstract][Full Text] [Related]
5. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer. Caparica R; Richard F; Brandão M; Awada A; Sotiriou C; de Azambuja E Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175 [TBL] [Abstract][Full Text] [Related]
7. A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Mahtani R; Holmes FA; Badve S; Caldera H; Coleman R; Mamounas E; Kalinsky K; Kittaneh M; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Vogel C; Clin Breast Cancer; 2020 Jun; 20(3):e251-e260. PubMed ID: 32139271 [TBL] [Abstract][Full Text] [Related]
8. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2 Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163 [TBL] [Abstract][Full Text] [Related]
9. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237 [TBL] [Abstract][Full Text] [Related]
10. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717 [TBL] [Abstract][Full Text] [Related]
11. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534 [TBL] [Abstract][Full Text] [Related]
12. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Turner NC; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M Ann Oncol; 2019 May; 30(5):774-780. PubMed ID: 30860570 [TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials. Fillbrunn M; Signorovitch J; André F; Wang I; Lorenzo I; Ridolfi A; Park J; Dua A; Rugo HS BMC Cancer; 2022 Sep; 22(1):1002. PubMed ID: 36131248 [TBL] [Abstract][Full Text] [Related]
14. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488 [TBL] [Abstract][Full Text] [Related]
15. Alpelisib in the treatment of metastatic HR+ breast cancer with Mavratzas A; Marmé F Future Oncol; 2021 Jan; 17(1):13-36. PubMed ID: 32964734 [TBL] [Abstract][Full Text] [Related]
16. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740 [TBL] [Abstract][Full Text] [Related]
17. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer. Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448 [TBL] [Abstract][Full Text] [Related]
19. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675 [TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]